PPARA and Alzheimer disease: In this context, the potential role of PPARα in the therapy of AD was assessed [59] according to its role in the progressive deposition of Aβ proteins in the brain parenchyma [82] or in the mutation of α-synuclein that leads to Aβ misfolding and aggregation [78], processes that trigger the activation of glial and other immune/inflammatory cells [78], which in turn, release inflammatory cytokines, chemokines, and various neurotoxic substances that induce neurodegeneration within the substantia nigra [78,79,80,81].